Original research
by
McLean, Katherine & Philip R. Kavanaugh
Release Date
2022
Geography
USA
Language of Resource
English
Full Text Available
No
Open Access / OK to Reproduce
No
Peer Reviewed
Yes
Objective
Little is known about the circumstances and motivations that surround buprenorphine diversion, particularly within the context of treatment expansion.
Findings/Key points
Across our typology, market demand in the form of unmet need for buprenorphine was the major driver of diversion, suggesting that “supply-side interventions” intended to again limit access to BMT may be counterproductive.
Design/methods
In-depth interviews (n=27)
Keywords
Policy/Regulatory
Substitution/OAT
Diversion
